<DOC>
	<DOCNO>NCT00721396</DOCNO>
	<brief_summary>Primary :1.To demonstrate sufficient immune response rMenB+OMV NZ , give concomitantly routine infant vaccine healthy infant 2 , 4 6 2 , 3 4 month age , measure percentage subject serum bactericidal activity ( SBA ) titer ≥1:5 , 1 month third vaccination Secondary : To demonstrate immunogenicity routine infant vaccine , give concomitantly rMenB+OMV NZ healthy infant 2 , 3 4 month age , non-inferior routine infant vaccine give without rMenB+OMV NZ . 2 . To demonstrate immunogenicity rMenB+OMV NZ give concomitantly routine infant vaccine non-inferior rMenB+OMV NZ give without routine infant vaccine 2 , 4 6 month age . 3 . To assess prevalence meningococcal B antibody study period evaluation SBA , baseline 1 month third vaccination , subjects- receive routine infant vaccine without rMenB+OMV NZ .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Meningococcal B Recombinant Vaccine Administered With Without Routine Infant Vaccinations Healthy Infants According Different Immunization Schedules</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy 2month old infant ( 5589 day , inclusive ) , bear full term pregnancy estimate gestational age ≥ 37 week birth weight ≥ 2.5 kg ; For parent/legal guardian give write informed consent nature study explain . History meningococcal B C vaccine administration ; prior vaccination routine infant vaccine ( Diphtheria , Tetanus , Pertussis , Polio , Haemophilus influenzae type b ( Hib ) , Pneumococcal antigens ) ; Previous ascertain suspected disease cause N. meningitidis ; History severe allergic reaction previous vaccination hypersensitivity vaccine component ; Significant acute chronic infection within previous 7 day axillary temperature major equal to38 degree within previous day ; Antibiotics within 6 day prior enrollment ; Any serious chronic progressive disease ; Known suspect impairment alteration immune system ; Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation .</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Meningococcal disease ,</keyword>
	<keyword>Neisseria meningitidis serogroup B ,</keyword>
	<keyword>Prevention ,</keyword>
	<keyword>Vaccination ,</keyword>
	<keyword>Infants</keyword>
</DOC>